Fibrolamellar CarcinomaSymptoms, Doctors, Treatments, Advances & More
Fibrolamellar Carcinoma Overview
Learn About Fibrolamellar Carcinoma
- Fibrolamellar carcinoma
- Eosinophilic glassy cell hepatoma
- Eosinophilic hepatocellular carcinoma with lamellar fibrosis
- FHCC
- FL-HCC
- Fibrolamellar hepatocarcinoma
- Fibrolamellar hepatocellular carcinoma
- Fibrolamellar oncocytic hepatoma
- Hepatocellular carcinoma with increased stromal fibrosis
- Polygonal cell hepatocellular carcinoma with fibrous stroma
Skip Viragh Outpatient Cancer Center
Dr. Mark Yarchoan is a physician–scientist based in Baltimore who specializes in the treatment and study of gastrointestinal cancers, with a particular focus on liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). He received his undergraduate degree from Amherst College and his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, followed by a fellowship in medical oncology at the Johns Hopkins University School of Medicine, where he joined the faculty in 2018. Dr. Yarchoan leads a research laboratory dedicated to developing novel immunotherapies for liver cancers. His translational research program integrates analyses of clinical trial biospecimens with preclinical modeling to identify and overcome barriers to effective antitumor immunity. A major focus of his work is the development of therapeutic cancer vaccines for hepatobiliary malignancies. He serves as Principal Investigator on multiple clinical trials for hepatobiliary cancers, contributes to international guideline committees for liver cancer, and is a member of the Johns Hopkins Graduate Training Programs in Cellular and Molecular Medicine and Immunology. Dr. Yarchoan’s contributions have been recognized with numerous honors, including the ASCO Young Investigator Award, the Conquer Cancer Foundation Career Development Award, the Mark R. Clements Award from the Cholangiocarcinoma Foundation, and the Blue Faery Award for Excellence in Liver Cancer Research. Dr. Yarchoan is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Pancreatic Cancer, and Hepatectomy.
ETSU Physicians & Associates- Surgery
. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Familial Pancreatic Cancer, Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection.
Hospital Of The University Of Pennsylvania Radiology
. Dr. Nadolski is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Chylous Ascites, Kimura Disease, Fibrolamellar Carcinoma, Liver Embolization, and Gastrostomy.
Summary: The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in patients with FL-HCC or other cancer entities carrying the DNAJB1-PRKACA fusion transcript as adjuvant treatment
Summary: The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

